Blueprint Medicines Corp (BPMC) SEC Filing 8-K Material Event for the period ending Wednesday, March 6, 2019

Blueprint Medicines Corp

CIK: 1597264 Ticker: BPMC

View differences made from one to another to evaluate Blueprint Medicines Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Blueprint Medicines Corp.


Assess how Blueprint Medicines Corp's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Blueprint Medicines Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Blueprint Medicines Corp provided additional information to their SEC Filing as exhibits

Ticker: BPMC
CIK: 1597264
Form Type: 8-K Corporate News
Accession Number: 0001558370-19-001726
Submitted to the SEC: Fri Mar 08 2019 5:00:27 PM EST
Accepted by the SEC: Fri Mar 08 2019
Period: Wednesday, March 6, 2019
Industry: Pharmaceutical Preparations
  1. Event for Officers
  2. Financial Exhibit

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: